Novanta (NOVT) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached $248 million, up 1.4% year-over-year, driven by acquisitions and favorable currency, with record new product revenue and strong bookings momentum.

• Net income for Q3 2025 was $10.7 million, down from $19.2 million in Q3 2024, with diluted EPS at $0.30; adjusted EPS rose to $0.87.

• Operating income fell 32.9% to $21.8 million due to higher SG&A, restructuring, and R&D expenses.

• Medical markets accounted for 53% of year-to-date revenue, with medical consumables and intelligent subsystems driving growth.

• Strategic focus remains on medical technologies, consumables, embedded software, and physical AI/robotics, with 20 new products launched year-to-date.

Financial highlights

• Q3 2025 non-GAAP adjusted gross profit was $115 million (46.5% margin), up 30 bps year-over-year; GAAP gross margin was 44.8%.

• Adjusted EBITDA reached $58.1 million (23.4% margin), up 2% year-over-year and 11% sequentially.

• Operating cash flow was $8.5 million, impacted by higher inventory, tax payments, and restructuring/acquisition costs.

• Net debt increased to $368 million (net leverage 1.7x) at quarter-end.

• Cash and cash equivalents at quarter-end were $89.2 million, with $543.4 million available under the revolving credit facility.

Outlook and guidance

• Q4 2025 revenue expected at $253–$257 million; adjusted EPS $0.87–$0.93; adjusted EBITDA $62–$65 million.

• Full-year 2025 revenue guidance is $975–$979 million; adjusted EPS $3.24–$3.30; adjusted EBITDA $222–$225 million.

• 2026 baseline outlook: mid-single-digit organic growth, led by advanced surgery and robotics/automation.

• Management expects to complete the 2025 restructuring program by end of 2026, with total charges around $20 million.

• Capital expenditures for 2025 are projected at $15–$20 million.